What is Vioxx?
VIOXX was developed in Canada by Merck Frosst Canada Ltd., a division of Merck
& Co. Inc. Its primary function was the relief of pain and inflammation experienced by over 350 million people worldwide who suffered from arthritis.
Vioxx was in a drug family named NSAIDS (non-steroidal anti-inflammatory drugs)
and acted by suppressing enzymes that produced pain and inflammation. Unfortunately, before the introduction of
VIOXX and Celebrex, the medications also had side effects which included gastro-intestinal bleeding and stomach ulcers. This happened because these drugs suppressed both the COX-1 and COX-2 enzymes. VIOXX was considered to be a
highly-effective drug because in solely inhibiting COX-2 it provided the pain and inflammation relief without the stomach upset.
What went wrong?
In a study to investigate whether persons on Vioxx had a lesser likelihood of developing pre-cancerous colorectal
polyps, the medical records of 1.4 million people insured by Kaiser Permanente, a large U.S. health-maintenance organization.
Just 18 months into the study, results indicated that patients on
Vioxx were 2x more likely to experience an adverse cardiovascular event such as a heart attack or stroke. If on a dosage of 50mg. or more of
Vioxx a day, the risk of a heart attack or stroke increased to
3 times more likely than someone on another medication or sugar pill.
Patients who have taken Vioxx and have experienced any of the
above symptoms and who are interested in learning more about
their legal rights can contact Rochon Genova at 1-866-881-2292
or complete the following online Medical Questionnaire.